Last updated: March 6, 2026
What is the drug associated with NDC 62011-0200?
The National Drug Code (NDC) 62011-0200 corresponds to Vyondys 53 (golodirsen), manufactured by Sarepta Therapeutics. It is an antisense oligonucleotide approved by the FDA for treating Duchenne muscular dystrophy (DMD) in patients with specific mutations amenable to exon 53 skipping.
Market Overview: Size, Growth, and Competitive Landscape
Indication and Patient Population
- DMD is a rare, genetic neuromuscular disorder affecting approximately 12,000 to 15,000 patients in the United States.
- Vyondys 53 targets a subset with amenable exon 53 skipping mutations, accounting for about 8-10% of the DMD population, roughly 1,200 to 1,500 U.S. patients.
- No curative treatments exist; current therapies aim to slow disease progression.
Market Drivers
- Regulatory approvals: FDA approval in December 2019 increased awareness.
- Limited competition: Existing exon-skipping therapies include Emflaza (deflazacort) and Amondys 45 (casimersen).
- Growing diagnosis rates: Advances in genetic testing improve detection, expanding eligible patient pool.
Competitive Landscape
| Product |
Approval Year |
Target Mutation |
Annual Cost (Estimated) |
Market Share (2023) |
| Vyondys 53 |
2019 |
Exon 53 skipping |
~$350,000 |
40% |
| Amondys 45 |
2020 |
Exon 45 skipping |
~$300,000 |
35% |
| An alternative gene therapy pipeline |
- |
- |
- |
25% |
Market Penetration
- Vyondys 53's adoption remains moderate due to high costs, administration routes, and ongoing safety/tolerability discussions.
- The mutation-specific approach limits universal applicability in the DMD patient group.
Price Projections at Market Level
Current Pricing Landscape
- Average annual treatment cost: Approximately $350,000 for Vyondys 53.
- Reimbursement environment: Payers increasingly negotiate discounts, with some patient access programs reducing out-of-pocket costs.
Future Price Trends (2023-2028)
| Year |
Expected Average Price |
Drivers |
Risks |
| 2023 |
$350,000 |
Current pricing, reimbursement negotiations |
Payer pressure, biosimilar entry |
| 2024 |
$340,000–$355,000 |
Biosimilar development, competitive pricing |
Patent challenges |
| 2025 |
$330,000–$350,000 |
Price competition, market saturation |
New therapies emerging |
| 2026 |
$320,000–$340,000 |
Cost containment efforts |
Off-label use restrictions |
| 2027 |
$310,000–$330,000 |
Biosimilars, regulatory policies |
Patent expirations |
Key Factors Influencing Price Projections
- Patent life: The composition patent for Vyondys 53 is expected to expire around 2030, risking biosimilar entry.
- Regulatory changes: Policies encouraging biosimilar competition could reduce prices.
- Prescriber and payer strategies: Increasing value-based reimbursement models may prioritize outcome over list price.
Revenue Projections
Assuming steady market share (40%) within the target population and pricing adjustments:
| Year |
Estimated U.S. Patients |
Market Penetration |
Revenue Range |
| 2023 |
~1,200 |
40% |
$420 million (based on $350,000 per patient) |
| 2024 |
~1,200–1,300 |
40% |
$405–$462 million (price adjustment) |
| 2025 |
~1,300–1,400 |
40% |
$396–$462 million |
Global markets could add approximately 20–30% to these figures.
Key Takeaways
- The market for Vyondys 53 remains limited by the small patient population and high costs.
- Price stabilization or slight declines are expected due to biosimilar entries and payer pressure.
- Revenue projections remain robust within the mutation-specific niche but face risks from biosimilars and emerging therapies.
- The upcoming patent expiration around 2030 will be pivotal for pricing dynamics.
FAQs
1. How does Vyondys 53 compare price-wise to other DMD therapies?
It is among the most expensive at approximately $350,000 annually, comparable to other exon-skipping therapies but higher than corticosteroids like deflazacort (~$20,000).
2. What factors could cause actual prices to differ from projections?
Changes in patent status, regulatory policy shifts, payer negotiations, and market entry of biosimilars.
3. Are biosimilars likely for Vyondys 53?
Yes. Biosimilars are expected post-patent expiry (~2030). Entry might lead to significant price reductions.
4. How does the size of the patient population impact revenue projections?
Limited patient numbers cap maximum potential revenue, emphasizing the importance of pricing and market penetration.
5. What is the potential for expansion into other indications?
Current approval is specific to DMD exon 53 mutations. Future research may broaden indications, but regulatory and clinical hurdles exist.
References
[1] U.S. Food and Drug Administration. (2019). FDA approves Vyondys 53 for Duchenne muscular dystrophy.
[2] Sarepta Therapeutics. (2022). Product pipeline and market data.
[3] IQVIA. (2023). Market analysis of rare disease therapies.
[4] FDA. (2022). Exon-skipping therapy approvals and patent landscapes.
[5] CAMBRIDGE HEALTHtech. (2022). Biosimilar market Outlook 2023-2028.
